Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:37:18.417Z.
Calculation as of: 2026-10-06T21:37:18.417Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d19fbcbfe88228e771d1365594a8990eb95a9f33d90bd822f782d755a125eeec
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. (IRWD) | $597.55M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | N/A | 4.91 | 4.34 | 3.76 |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $578.40M | N/A | N/A | N/A | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $571.13M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $630.63M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
4.7
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute